562 results about "Vesicle" patented technology

An implantable medical device is provided for controlled drug delivery within the bladder, or other body vesicle. The device may include at least one drug reservoir component comprising a drug; and a vesicle retention frame which comprises an elastic wire having a first end, an opposing second end, and an intermediate region therebetween, wherein the drug reservoir component is attached to the intermediate region of the vesicle retention frame. The retention frame prevents accidental voiding of the device from the bladder, and it preferably has a spring constant selected for the device to effectively stay in the bladder during urination while minimizing the irritation of the bladder.

The invention relates to a medicament carrier and a preparation method thereof, in particular to a medicament delivery system comprising biodegradable polymer vesicles with asymmetric membranes. The invention discloses the biodegradable polymer vesicles and preparation and application thereof. The biodegradable polymer vesicles are prepared from A-B-C type block polymer, wherein a block A is polyethylene glycol (PEG) distributed on outer surfaces of the vesicles; a block B is hydrophobic biodegradable polymer to form the nucleuses of the vesicles; and a block C is polyelectrolyte distributed on inner walls of the vesicular membranes and used for efficiently loading medicaments with opposite electric charge. The biodegradable polymer vesicles are formed in aqueous solution directly, can efficiently load protein and polypeptide medicaments, nucleic acid medicaments and micro-molecular medicaments, and are expected to be applied to the protein therapy and the combination therapy of cancers.

A vesicle dispersion comprising (A) sucrose fatty acid ester, (B) a sphingosine and/or its derivative, and (C) an aqueous component and a cosmetic composition comprising the vesicle dispersion are disclosed. The vesicle dispersion can stably contain sphingosines such as a ceramide, excelling in a moisturizing effect of the skin, and the cosmetic composition comprising the vesicle dispersion exhibits an excellent moisturizing effect, storage stability, and the like.

The invention discloses a preparation method of a metal polyphenol vesicle material with a micrometer/nanometer multilayer composite structure. The metal polyphenol vesicle material with the multilayer composite structure is obtained by etching polyphenol by taking a metal organic framework compound serving as a template. The precise control on an internal structure of a vesicle and the surface roughness of the vesicle is realized through controlling experiment parameters such as etching time and a pH value. The functionality of the obtained vesicle material is also greatly enriched by introducing a polyphenol structural unit to an assembly system, and the preparation method is favorably applied to aspects such as catalytic reaction and drug delivery.

A closed-loop insulin delivery system is described. More particularly, the presently disclosed insulin delivery system can comprise glucose-responsive vesicles that release insulin in response to hypoxia triggered by enzymatic reduction of glucose. In addition or as an alternative to insulin, the delivery system can release other diabetes treatment agents, such as non-insulin-based diabetes treatment agents. The vesicles can be prepared from a hypoxia sensitive polymer, such as a hypoxia-sensitive hyaluronic acid (HS-HA). The HS-HA can comprise hydrophobic groups that can be reduced in hypoxicenvironments to form hydrophilic groups. The vesicles can be loaded into microneedles and microneedle array patches for use in the treatment of diabetes or to otherwise regulate blood glucose levelsin subjects in need of such treatment.

Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.

The invention relates to an acid-sensitive amphipathic tri-block polymer. The polymer is composed of a polyethylene glycol-acid sensitive segment 1-acid sensitive segment 2 tri-block copolymer, wherein the acid sensitive segment 1 is poly(acrylamidophenylboronic acid); the acid sensitive segment 2 is poly(aminoacyl dimethyl-ethylenediamine); the molecular weight of the polyethylene glycol is 2000-5000, the molecular weight of the acid sensitive segment is 2000-6000, and the molecular weight of the acid sensitive segment is 1000-2000. The invention further relates to application of the acid sensitive amphipathic tri-block polymer in preparation of polymer nano-vesicle for co-delivering drug and perfluorooctylbromide. The nano-vesicle has a uniform nano-diameter, can stably circulate in a body and can be enriched in a tumor position, has excellent capability of reinforcing ultrasonic development to realize application of ultrasonic development under diagnostic ultrasound, and has ultrasonic sensitivity to stimulate the cavitation effect under a condition of low-frequency high-energy ultrasonic-radiation so as to realize controllable release of drugs.

A pharmaceutical preparation comprising magnetic vesicular particles, wherein the magnetic vesicular particles each include one or more magnetic microparticles within a lipid membrane, the magnetic microparticle having particulate gold attached to the surface of the magnetic microparticles and further having an organic compound bound to the particulate gold; and the vesicular particles meet the following requirement:

0.02≦R/(r×100)≦0.03

wherein R is an average particle size of the magnetic vesicular particles and r is an average particle size of the magnetic microparticles included in the magnetic vesicular particles.

A method for accumulating drugs or other chemicals within synthetic, lipid-like vesicles by means of a pH gradient imposed on the vesicles just prior to use is described. The method is suited for accumulating molecules with basic or acid moieties which are permeable to the vessels membranes in their uncharged form and for molecules that contain charge moieties that are hydrophobic ions and can therefore cross the vesicle membranes in their charged form. The method is advantageous over prior art methods for encapsulating biologically active materials within vesicles in that it achieves very high degrees of loading with simple procedures that are economical and require little technical expertise, furthermore kits which can be stored for prolonged periods prior to use without impairment of the capacity to achieve drug accumulation are described. A related application of the method consists of using this technology to detoxify animals that have been exposed to poisons with basic, weak acid or hydrophobic charge groups within their molecular structures.

The present invention belongs to the field of polymer materials and biomedical engineering, and particularly relates to a polylactic acid stereo complex magnetic nanometer vesicle preparation method, which specifically comprises that: L-polylactic acid and D-polylactic acid respectively react with polyethylene glycol to synthesize two different block copolymers, then stereo compounding is performed, and nanometer magnetic particles are entrapped so as to form the polylactic acid stereo complex magnetic nanometer vesicle adopting the hydrophobic stereo composite polylactic acid as the film and having the inner layer and the outer layer being the hydrophilic polyethylene glycol chains, wherein the obtained nanometer vesicle has excellent stability due to the strong intermolecular interaction of the stereo complex, and the magnetic particles are wrapped in the compact polylactic acid film structure so as not to be easily leaked. According to the present invention, the magnetic nanometer vesicles can be used as the enhancement contrast agent in the clinical magnetic resonance imaging, and can further load drugs or biological macromolecules so as to be used as the release controlling nanometer carrier of drug or gene therapy.

The invention provides a cross-linked biologically degradable carrier polymer, a micelle and a vesicle, and a preparation method and an application of the cross-linked biologically degradable carrier polymer, micelle and vesicle, belonging to the field of biological medical material and solving a poor stability problem of the existing polymer micelle and vesicle. The carrier polymer is an A-B-C tri-block polymer, wherein the block A is polyethylene glycol, the block B is the polyethylene glycol containing functional groups in a lateral chain, and the block C is biologically degradable polyester. The invention also provides the polymer micelle and vesicle, which is formed by self assembly of the carrier polymer, wherein the size of the polymer micelle is 20-1000nm, and the size distribution is 0.01-0.50; the size of the vesicle is 20-1000nm, and the size distribution is 0.01-0.50. The polymer micelle provided by the invention can package fat-soluble matters; and the polymer vesicle canpackage water-soluble matters and the fat-soluble matters at the same time; and the polymer micelle or the vesicle has better mechanical strength and stability because the polymer micelle or the vesicle contains a transitional layer formed by the cross-linked block B.

Combination vaccines for treating or preventing Neisseria meningitidis infection are described. The vaccines include Neisseria meningitidis serogroup B proteoliposomic vesicles and Neissera meningitidis serogroup C conjugated oligosaccharides.

The invention relates to a non-ionic surface active agent vesicle capable of restoring skin micro-ecology. The vesicle is characterized by comprising the following components by weight percent: 0.1% to 40% of a non-ionic surface active agent, 0.1% to 40% of an active composition for restoring skin micro-ecology, and 1.0% to 60% of water soluble alcohol. The invention also discloses a preparation method of the vesicle. The method comprises the following steps: A, mixing the active composition for restoring skin micro-ecology and the water soluble alcohol, heating to 70 to 80 DEG C, and stirring until the mixture is completely dissolved; B, preparing an non-ionic surface active agent composition; C, mixing the substance obtained from step A and the substance obtained from step B, adding a proper amount of deionized water, performing thermal insulation for 10 minutes at the temperature of 70 to 80 DEG C, cooling, and adding a proper amount of an anti-corrosive agent. The vesicle and the preparation method have the advantages that three types of active substances, namely coconut freeze-dried powder, burdock extract and flaxseed extract, can be simultaneously coated; the normal flora micro-ecology of skin can be restored; the stability of active substances is improved, and the transdermal effect is good.

The invention relates to the technical field of biological separation and extraction, in particular to an extracting method of extracellular vesicles. The method comprises the steps that a biologicalsample is provided; the biological sample is in contact with a capturing surface at least twice on the condition that impurities in the biological sample are partially or wholly reserved on the capturing surface, wherein the impurities are partial or whole other substances except the extracellular vesicles in the biological sample, and the capturing surface comprises an inner surface and/or outersurface of a spherical-particle porous material; when the impurities are partially or wholly reserved on the surface of a capture, breakthrough liquid is extracted liquid containing the extracellularvesicles; or the breakthrough liquid is further concentrated. By means of the method, the epicyte vesicles can be quickly separated and purified, the separation operation is simple, the single use cost is low, the separated sample in high in purity, the bioactivity of the sample is kept good, and the extracting method is applied to fundamental research in the aspects of biomarker discovery, biotherapy and the like and industrial production.

The invention discloses a nano cell membrane drug-loaded vesicle, a preparation method and application thereof. The preparation method is characterized in that through a physical extrusion technology,drug coating is carried out in the process of forming nanoscale cell membrane vesicles, no influence is generated on the activity of a coated drug, the in-vivo circulation time of the drug can be prolonged, the drug targeting ability is improved, and directional slow release of the drug is realized. The preparation method comprises the steps of cell membrane acquisition and cell membrane nano-vesicle preparation. Specific cell delivery of the drug targeting specific part can be realized, so that the drug fully plays a therapeutic role, and liver and kidney injury caused by one-time massive drug aggregation in the liver or kidney is prevented. Dynamic changes in a drug body can be tracked through probe wrapping.

The invention discloses a bionic cell membrane nanoparticle as well as a preparation method and application thereof. The bionic cell membrane nanoparticle comprises a tumor cell membrane vesicle and a chemotherapeutic drug, wherein the chemotherapeutic drug is encapsulated in the tumor cell membrane vesicle, and a photothermal agent or a photosensitizer is loaded in the tumor cell membrane vesicle. An STING activator encapsulated in the bionic cell membrane nanoparticle can activate an STING pathway in an antigen-presenting cell (APCs); meanwhile, a preparation is taken by tumor cells through the homologous adhesion characteristic of a tumor cell membrane, and the photothermal agent generates high temperature or the photosensitizer generates singlet oxygen (ROS) under the irradiation of exogenous laser so as to promote the release of tumor-associated antigens, so that primary tumors are converted into therapeutic STING activated vaccines. The therapeutic STING vaccines can generate a strong anti-tumor effect in malignant tumors.

The present disclosure features compositions and methods related to the detection and molecular profiling of extracellular vesicles using fluorescent probes. These compositions and methods leverage the unique optoelectrical properties of quantum dots and fluorescently labeled nanoparticles, which allows reliable, real-time detection of extracellular vesicles and vesicle surface bound or lumenal molecules.